p38MAPK inhibitor SB203580 sensitizes human SNU-C4 colon cancer cells to exisulind-induced apoptosis

Oncology Reports

Volumn 16, Issue 5, 2006, Pages 1131-1135

  Lim, Soo Jeong ^a,b   Lee, Young Ju ^b   Lee, Eunmyong ^a  

^a Sejong University   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Apoptosis; Colon cancer; Exisulind; p38MAPK; SB203580

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; FLAVONOID; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; SULINDAC; SULINDAC SULFONE;

APOPTOSIS; ARTICLE; CELL STRAIN HCT116; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; COLONIC NEOPLASMS; FLAVONOIDS; HCT116 CELLS; HUMANS; IMIDAZOLES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; SULINDAC;

EID: 39049183692     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.5.1131     Document Type: Article

References (28)

1. Stoner GD, Budd GT, Ganapathi R, et al: Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol 470: 45-53, 1999.
2. Goluboff ET, Shabsigh A, Saidi JA, et al: Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53: 440-445, 1999. (Pubitemid 29063347)
3. Whitmarsh AJ and Davis RJ: Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74: 589-607, 1996. (Pubitemid 26343761)
4. Milella M, Precupanu CM, Gregorj C, et al: Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des 11: 2779-2795, 2005. (Pubitemid 41051884)
5. English J, Pearson G, Wilsbacher J, et al: New insights into the control of MAP kinase pathways. Exp Cell Res 253: 255-270, 1999.
6. Lee JS, Lee JJ and Seo JS: HSP70 deficiency results in activation of c-Jun N-terminal Kinase, extracellular signal-regulated kinase, and caspase-3 in hyperosmolarity-induced apoptosis. J Biol Chem 280: 6634-6641, 2005.
7. Lieu CH, Liu CC, Yu TH, et al: Role of mitogen-activated protein kinase in taxol-induced apoptosis in human leukemic U937 cells. Cell Growth Differ 9: 767-776, 1998. (Pubitemid 28425873)
8. Xu C, Shen G, Yuan X, et al: ERK and JNK signaling pathways are involved in the regulation of activator protein 1 and cell death elicited by three isothiocyanates in human prostate cancer PC-3 cells. Carcinogenesis 273: 435-445, 2005.
9. Rice PL, Goldberg RJ, Ray EC, et al: Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res 61: 1541-1547, 2001. (Pubitemid 34292585)
10. Rice PL, Kelloff J, Sullivan H, et al: Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2: 885-892, 2003.
11. Rice PL, Peters SL, Beard KS, et al: Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways. Mol Cancer Ther 5: 746-754, 2006.
12. Soh JW, Mao Y, Kim MG, et al: Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res 6: 4136-4141, 2000.
13. Thompson WJ, Piazza GA, Li H, et al: Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 60: 3338-3342, 2000. (Pubitemid 30482142)
14. Czibere A, Prall WC, Zerbini LF, et al: The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome. Cell Cycle 4: 812-817, 2005. (Pubitemid 41353834)
15. Sun Y and Sinicrope FA: Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. Mol Cancer Ther 4: 51-59, 2005. (Pubitemid 40268066)
16. Yin Z, Patel SJ, Wang WL, et al: Peptide inhibitors of dengue virus NS3 protease. Part 1: Warhead. Bioorg Med Chem Lett 16: 40-43, 2005.
17. Li H, Liu L, David ML, et al: Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation. Biochem Pharmacol 64: 1325-1336, 2002. (Pubitemid 35248250)
18. Valladares A, Alvarez AM, Ventura JJ, et al: p38 mitogen-activated protein kinase mediates tumor necrosis factor-alpha-induced apoptosis in rat fetal brown adipocytes. Endocrinology 141: 4383-4395, 2000. (Pubitemid 32055112)
19. Kondoh M, Tasaki E, Araragi S, et al: Requirement of caspase and p38MAPK activation in zinc-induced apoptosis in human leukemia HL-60 cells. Eur J Biochem 269: 6204-6211, 2002. (Pubitemid 35461833)
20. Kim JY, Choi JA, Kim TH, et al: Involvement of p38 mitogen-activated protein kinase in the cell growth inhibition by sodium arsenite. J Cell Physiol 190: 29-37, 2002.
21. Zhang H, Vollmer M, De Geyter M, et al: Apoptosis and differentiation induced by staurosporine in granulosa tumor cells is coupled with activation of JNK and suppression of p38 MAPK. Int J Oncol 26: 1575-1580, 2005.
22. Nakada S, Kawano T, Saito-akita S, et al: MEK and p38MAPK inhibitors potentiate TNF-alpha induced apoptosis in U937 cells. Anticancer Res 21: 167-171, 2001.
23. Vega MI, Huerta-Yepaz S, Garban H, et al: Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 23: 3530-3540, 2004. (Pubitemid 38658419)
24. Lin JC, Chang SY, Hsieh DS, et al: Modulation of mitogen-activated protein kinase cascades by differentiation-1 protein: acquired drug resistance of hormone independent prostate cancer cells. J Urol 174: 2022-2026, 2005.
25. Minami T, Adachi M, Kawamura R, et al: Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Clin Cancer Res 11: 5248-5256, 2005. (Pubitemid 41003713)
26. Ohishi T, Kishimoto Y, Miura N, et al: Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane. Cancer Lett 177: 49-56, 2002. (Pubitemid 34102398)
27. Chan DC, Earle KA, Zhao TL, et al: Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res 8: 904-912, 2002. (Pubitemid 34742124)
28. Soriano AF, Helfrich B, Chan DC, et al: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59: 6178-6184, 1999. (Pubitemid 30035640)